New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:16 EDTSPPI, ARNA, GTAT, CASI, BDSI, DISH, ENDP, NQOn The Fly: Pre-market Movers
HIGHER: DISH (DISH), up 2.4% following positive mention in this weekend's Barron's, contending the shares could climb 20%... BioDelivery Sciences (BDSI), up 15% after announcing results from its Endo buprenorphine trial with an Endo (ENDP) division... CASI Pharmaceuticals (CASI), up 3.7% after confirming that it received FDA orphan drug designation for a drug... Spectrum (SPPI), up 3% after being granted accelerated approval for Beleodaq from FDA. LOWER: GT Advanced (GTAT), down 10% after downgraded at UBS and Cannaccord... NQ Mobile (NQ), down 3.5% after Muddy Waters says the company has likely already decided to fire PwC... Arena Pharmaceuticals (ARNA), down 3% after Chairman, President and CEO Jack Lief sold 223,525 shares of the company's common stock pursuant to a Rule 10b5-1 trading plan on July 1, according to a regulatory filing from late Thursday.
News For DISH;GTAT;NQ;BDSI;ARNA;ENDP;CASI;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 15, 2014
09:21 EDTNQNQ Mobile volatility elevated into reporting Q1, Q2, Q3 results
Subscribe for More Information
09:10 EDTNQNQ Mobile to report Q1, Q2, Q3 results on Dec. 18
December 12, 2014
16:56 EDTCASICASI Pharmaceuticals files to sell 5.4M shares of common stock for holders
Subscribe for More Information
December 11, 2014
17:04 EDTENDPEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
14:23 EDTNQChinese report casts doubt on NQ Mobile co-CEO departure, Muddy Waters says
Subscribe for More Information
06:24 EDTDISHDISH plans to leave broadcast channels out of basic online TV package, WSJ says
Subscribe for More Information
05:18 EDTDISHNexstar, DISH reach distribution agreement
Nexstar Broadcasting (NXST) announced that it reached a new distribution agreement with DISH Network (DISH) allowing the satellite television provider the right to continue to air Nexstarís programming. The agreement covers Nexstarís broadcast platform inclusive of 60 network affiliated and local stations in 46 markets. On Monday, December 8, Nexstar granted DISH an extension until 11:59 p.m. ET tonight to the companiesí previous agreement.
December 10, 2014
08:58 EDTNQNQ Mobile holder RPL agrees to additional two-year voluntary lock-up
NQ Mobile stated that, as a sign of confidence in the future of the company, RPL Limited, a substantial shareholder of NQ Mobile which is owned and controlled by the founders of NQ, has agreed to an additional two-year voluntary lock-up that will expire in December 2016. RPL is a limited liability company organized under the laws of the British Virgin Islands. As of October 15, , RPL held 50,352,941 Class B common shares, equivalent to approximately 10.07M ADSs, of NQ Mobile, representing approximately 11.3% of NQ Mobile's outstanding shares. RPL agreed it will not sell any of its shares until December 2016. In addition to the lock-up by RPL, the founders and NQ Mobile's senior management reiterate their intention to purchase additional shares in accordance with all applicable rules and regulations.
08:56 EDTNQNQ Mobile Co-CEO and Chairman Lin steps down
Subscribe for More Information
08:37 EDTNQNQ Mobile Co-CEO and Chairman Lin steps down
05:53 EDTDISHStocks with implied volatility movement; SPLS DISH
Subscribe for More Information
December 9, 2014
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
06:32 EDTDISHCitigroup calls on DISH to split into two companies
Subscribe for More Information
05:24 EDTDISHNexstar provides third extension to DISH distribution agreement
Nexstar Broadcasting (NXST) announced that it has provided the third extension of its distribution agreement with DISH Network (DISH) allowing the satellite television provider the right to continue to air Nexstarís highly rated programming until 11:59 p.m. ET on Wednesday, December 10. The agreement covers Nexstarís broadcast platform inclusive of 60 network affiliated and local stations in 46 markets. DISHís previous extension with Nexstar expires at 11:59 p.m. ET. Nextar stated that for over two months, it has been negotiating in good faith to establish a mutually agreeable contract with DISH and Nexstar remains hopeful that a resolution can be reached without a service interruption to viewers in affected markets.
December 8, 2014
12:28 EDTCASICASI Pharmaceuticals to host special shareholder meeting
Subscribe for More Information
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information
07:01 EDTBDSIBioDelivery Sciences completes randomization in trial of clonidine topical gel
BioDelivery Sciences announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. BDSI anticipates that topline results of the study will be available by the end of March 2015. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. In the trial, known as the RHAPSODY Study, subjects were randomized to receive either Clonidine Topical Gel or a placebo gel. Two hundred and sixty three adult subjects were randomized into the 12 week double-blind treatment phase of the study. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the U.S. Food and Drug Administration. FDA has granted Fast Track designation for the program, which recognizes the need of developing new therapies for this serious condition. BDSI plans to begin the second Phase 3 study during the first quarter of 2015.
06:47 EDTARNAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
06:45 EDTARNAArena says Eisai withdraws Belviq application in Canada
Subscribe for More Information
06:44 EDTARNAArena Pharmaceuticals says 'small number' of Belviq labels incomplete
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use